PTC Therapeutics insider plans 1,026-share sale

PTC Therapeutics insider Neil G. Almstead filed a Form 144 to potentially sell 1,026 shares of common stock through Fidelity Brokerage Services on NASDAQ around 01/07/2026.

Rhea-AI Filing Summary

PTC Therapeutics insider Neil G. Almstead filed a Form 144 to potentially sell 1,026 shares of common stock through Fidelity Brokerage Services on NASDAQ around 01/07/2026. The filing notes that these shares were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation.

As context, the company had 80,288,305 common shares outstanding. Over the prior three months, Neil G. Almstead reported selling 35,572 shares for gross proceeds of 2,852,153.65 on 11/24/2025, 71,928 shares for 6,001,524.59 on 11/25/2025, and 1,279 shares for 98,415.98 on 01/06/2026. Zheng Y. Almstead reported selling 54 shares for 4,155.17 on 01/06/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 144 filing for PTCT disclose?

The filing discloses that Neil G. Almstead plans a potential sale of 1,026 shares of PTC Therapeutics common stock through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 01/07/2026.

How many PTCT shares is Neil G. Almstead planning to sell?

The notice covers a proposed sale of 1,026 shares of PTC Therapeutics common stock in a single transaction routed through Fidelity Brokerage Services LLC.

How did Neil G. Almstead acquire the PTCT shares being sold?

The 1,026 shares to be sold were acquired on 01/05/2026 via restricted stock vesting from the issuer, with the nature of payment listed as compensation.

What recent PTCT stock sales by Neil G. Almstead are reported?

In the past three months, Neil G. Almstead reported selling 35,572 shares for 2,852,153.65 on 11/24/2025, 71,928 shares for 6,001,524.59 on 11/25/2025, and 1,279 shares for 98,415.98 on 01/06/2026.

Were there other related PTCT insider sales disclosed in this Form 144?

Yes. The filing shows that Zheng Y. Almstead, at the same address, sold 54 shares of common stock on 01/06/2026 for gross proceeds of 4,155.17.

How many PTCT shares were outstanding at the time of this notice?

The Form 144 lists 80,288,305 shares of common stock outstanding for PTC Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/07/2026 - 04:14 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001578850
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PTC THERAPEUTICS, INC.
SEC File Number	001-35969
Address of Issuer	500 WARREN CORPORATE CENTER DRIVE WARREN NEW JERSEY 07059
Phone	9082227000
Name of Person for Whose Account the Securities are To Be Sold	Almstead Neil Gregory
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1026	79498.38	80288305	01/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/05/2026	Restricted Stock Vesting	Issuer			1026	01/05/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Neil G. Almstead 500 Warren Corporate Center Drive Warren NJ 07059	Common	11/24/2025	35572	2852153.65
Neil G. Almstead 500 Warren Corporate Center Drive Warren NJ 07059	Common	11/25/2025	71928	6001524.59
Neil G. Almstead 500 Warren Corporate Center Drive Warren NJ 07059	Common	01/06/2026	1279	98415.98
Zheng Y. Almstead 500 Warren Corporate Center Drive Warren NJ 07059	Common	01/06/2026	54	4155.17

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution. The sale on 01/06/2026 occurred in the account of Zheng Y. Almstead who is the spouse of Neil G. Almstead.
Date of Notice	01/07/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Adam Gehring, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Neil G. Almstead
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)